Cytori’s Celution® System Approved in Australia for Processing and Delivering Adipose-Derived Regenerative Cells

  Cytori’s Celution® System Approved in Australia for Processing and
  Delivering Adipose-Derived Regenerative Cells

Business Wire

SAN DIEGO -- August 7, 2013

Cytori Therapeutics (NASDAQ: CYTX) has received notice from the Australian
Therapeutic Goods Administration (TGA) that the Celution® System is approved
for commercial use through inclusion on the Australian Registry of Therapeutic
Goods for autologous re-implantation or re-infusion of a patient’s
adipose-derived regenerative cells (ADRCs). The Celution® System produces
autologous (a patient’s own) ADRCs at the point-of-care which may then be used
for a range of injuries or conditions.

“Following an intensive two year review by the TGA, hospitals and physicians
in Australia will have full commercial access to the only closed-system,
point-of-care device which produces clinical-grade ADRCs for re-implantation
or re-infusion into the patient,” said David C. Oxley, Vice President Emerging
Markets for Cytori Therapeutics. “This approval establishes the foundation for
enabling treatment of critical unmet medical needs across a variety of
indications for patients in Australia.”

During the past two years, Dr. David Chin, MCh, PhD (Plast), FRCS, FRACS
(Plast) of Queensland, Australia worked with Cytori under a TGA Authorized
Prescriber Approval to treat a variety of conditions, particularly in the area
of soft tissue injury and limited blood flow.

“We have had very favourable outcomes in the 80 plus patients treated using
the Celution® System. Cases include breast reconstruction and patients who no
longer wish to have silicone breast implants. Additional medical conditions,
such as rheumatoid arthritis and soft tissue sports medicine related injuries
are included,” commented Dr. Chin. “I can attest to the healing power of these
cells based on the positive outcomes in my own clinical practice. In total, my
experience includes a variety of presenting conditions over two years. Being
able to access the patient’s own adipose derived regenerative cells during a
single procedure opens up a whole dimension of acute and chronic medical
conditions that may be addressed, including some previously considered
untreatable under conventional treatment modalities.”

Adipose tissue is considered the richest source of regenerative cells in the
body. These cells are comprised of a heterogeneous population of cells which
are collectively referred to as ADRCs. The heterogeneous nature of ADRCs are
believed to contribute to the healing process via multiple mechanisms, which
include cell-to-cell signaling, supporting improved blood flow and regulation
of the inflammatory response.

About Cytori

Cytori Therapeutics is developing cell therapies based on autologous
adipose-derived regenerative cells (ADRCs) to treat cardiovascular disease and
other medical conditions. Our scientific data suggest ADRCs improve blood
flow, moderate the inflammatory response and keep tissue at risk of dying
alive. As a result, we believe these cells can be applied across multiple
“ischemic” conditions. These therapies are made available to the physician and
patient at the point-of-care by Cytori’s proprietary technologies and
products, including the Celution System product family. www.cytori.com

Cautionary Statement Regarding Forward-Looking Statements

This communication includes forward-looking statements regarding events,
trends and business prospects, which may affect our future operating results
and financial position. Such statements are subject to risks and uncertainties
that could cause our actual results and financial position to differ
materially. Some of these risks and uncertainties include the challenges
inherent in convincing physicians and patients to adopt the new technology as
well as our history of operating losses, regulatory uncertainties, dependence
on third party performance, and other risks and uncertainties described under
the "Risk Factors" section in Cytori's Securities and Exchange Commission
Filings on Form 10-K and Form 10-Q. Cytori assumes no responsibility to update
or revise any forward-looking statements contained in this press release to
reflect events, trends or circumstances after the date of this press release.

Contact:

Cytori Therapeutics
Cytori Therapeutics, Australia
David Oxley
doxley@cytori.com
+1-858-337-3565
or
US Investors
Tom Baker
tbaker@cytori.com
+1-858-875-5258
or
Media
Megan McCormick
mmccormick@cytori.com
+1-858-875-5279
 
Press spacebar to pause and continue. Press esc to stop.